The effect of denosumab treatment on osteoclast precursor cells in postmenopausal osteoporosis

The effect of denosumab treatment on osteoclast precursor cells in postmenopausal osteoporosis

Bibliographic Details
Main Authors:	Andreas Fontalis, Fatma Gossiel, Marian Schini, Jennifer Walsh, Richard Eastell
Format:	Article
Language:	English
Published:	Elsevier 2020-10-01
Series:	Bone Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352187220302175

Similar Items

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
by: Lewiecki EM
Published: (2011-12-01)

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
by: Yong-Ki Min
Published: (2015-03-01)

Denosumab – a new medication in the treatment of postmenopausal osteoporosis
by: Radosław Słopień, et al.
Published: (2017-10-01)

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
by: Darbà J, et al.
Published: (2015-02-01)

Emerging treatments for postmenopausal osteoporosis – focus on denosumab
by: Piet Geusens
Published: (2009-06-01)

Phase I/III study to confirm bioequivalence and safe switching of proposed biosimilar denosumab in postmenopausal osteoporosis
by: Jean-Jacques Body, et al.
Published: (2020-10-01)

Safety and efficacy of denosumab in postmenopausal somen with osteoporosis
by: Dilsad Sindel, et al.
Published: (2020-10-01)

Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic Review
by: Shahin Nargesi, et al.
Published: (2022-07-01)

Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
by: Takako Suzuki, et al.
Published: (2017-06-01)

Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis
by: Yang Sun, et al.
Published: (2022-05-01)

Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adherence
by: Cairoli E, et al.
Published: (2015-10-01)

Denosumab for the treatment of osteoporosis
by: Michael R. McClung
Published: (2017-03-01)

Adherence to treatment with denosumab, its efficacy and safety in women with postmenopausal osteoporosis in clinical practice
by: N. V. Toroptsova, et al.
Published: (2016-01-01)

Long-term treatment options for postmenopausal osteoporosis: results of recent clinical studies of Denosumab
by: Zhanna E. Belaya, et al.
Published: (2018-04-01)

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
by: Jiaqi Wu, et al.
Published: (2018-08-01)

Osteoclast formation from circulating precursors in osteoporosis.
by: Jevon, M, et al.
Published: (2003)

Effects of 3-year denosumab treatment on hip structure in Japanese postmenopausal women and men with osteoporosis
by: Teruki Sone, et al.
Published: (2017-12-01)

Does the VDR gene polymorphism influence the efficacy of denosumab therapy in postmenopausal osteoporosis?
by: Anna Wawrzyniak, et al.
Published: (2023-01-01)

Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
by: Yi Chen, et al.
Published: (2021-04-01)

Effect of age and gender on serum growth differentiation factor 15 and its relationship to bone density and bone turnover
by: Lorenza Mattia, et al.
Published: (2023-06-01)

A review of denosumab for the treatment of osteoporosis
by: Miyazaki T, et al.
Published: (2014-04-01)

Osteoporosis in men: epidemiology and treatment with denosumab
by: Sidlauskas KM, et al.
Published: (2014-04-01)

EFFICACY OF DENOSUMAB RELATIVE TO OTHER OSTEOPOROSIS THERAPIES FOR PREVENTION OF FRACTURES IN POSTMENOPAUSAL OSTEOPOROSIS: RESULTS OF AN ADJUSTED INDIRECT AND MIXED TREATMENT COMPARISON
by: Freemantle, N, et al.
Published: (2010)

Correction: Efficacy of Denosumab in the Treatment of Postmenopausal Osteoporosis: One-year Follow-up, Single Center Study
by: İsmail Tunçekin, et al.
Published: (2023-12-01)

Effectiveness of Denosumab in Postmenopausal Osteoporosis Treatment: A 1-yr Follow-up Single-center Study
by: Nihal Tezel, et al.
Published: (2021-12-01)

Critical appraisal of denosumab in the treatment and prevention of postmenopausal osteoporosis and bone loss in patients undergoing hormone ablation
by: David L Kendler, et al.
Published: (2010-09-01)

Treatment options for postmenopausal osteoporosis
by: Walsh GM
Published: (2012-08-01)

The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review
by: Yilin Zhu, et al.
Published: (2020-05-01)

A randomized placebo-controlled trial of the efficacy of denosumab in Indian postmenopausal women with osteoporosis
by: Shailesh Pitale, et al.
Published: (2015-01-01)

High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis
by: Ishikawa K, et al.
Published: (2016-12-01)

Osteoclast formation from circulating precursors in primary and secondary osteoporosis.
by: Jevon, M, et al.
Published: (2000)

Denosumab, an effective osteoporosis treatment option for men
by: Sung Hye Kong
Published: (2022-09-01)

Denosumab treatment in patients with different courses of osteoporosis
by: Liudmila Ya. Rozhinskaya, et al.
Published: (2017-12-01)

Should denosumab treatment for osteoporosis be continued indefinitely?
by: Jane A. Noble, et al.
Published: (2021-04-01)

Albumin-adjusted calcium equation and reference interval for adjusted calcium. Data from the UK Biobank
by: Marian Schini, et al.
Published: (2020-10-01)

Advantages of using denosumab for osteoporosis
by: O. B. Ershova, et al.
Published: (2013-12-01)

THREE YEARS' EXPERIENCE WITH THE BIOLOGICAL AGENT DENOSUMAB USED TO TREAT WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS: EFFICACY, SAFETY AND TREATMENT ADHERENCE
by: N. V. Toroptsova, et al.
Published: (2017-07-01)

Immune Regulation of Osteoclast Function in Postmenopausal Osteoporosis: A Critical Interdisciplinary Perspective
by: Renqing Zhao
Published: (2012-01-01)

Follicle-Stimulating Hormone Increases the Risk of Postmenopausal Osteoporosis by Stimulating Osteoclast Differentiation.
by: Jie Wang, et al.
Published: (2015-01-01)

Denosumab is the first gene engineered agent for the treatment of osteoporosis
by: O A Nikitinskaya, et al.
Published: (2012-09-01)